MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

August 9, 2026 updated by: Healios K.K.

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.

Study Overview

Status

Terminated

Conditions

Study Type

Interventional

Enrollment (Actual)

206

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taichung, Taiwan, 40402
        • Athersys Investigational Site 603
      • Taipei, Taiwan, 10002
        • Athersys Investigational Site 601
      • Taoyuan City, Taiwan, 33305
        • Athersys Investigational Site 602
    • Arizona
      • Phoenix, Arizona, United States, 85013
        • Athersys Investigational Site 128
    • California
      • Palo Alto, California, United States, 94304
        • Athersys Investigational Site 122
      • Sacramento, California, United States, 95817
        • Athersys Investigational Site 127
    • Florida
      • Clearwater, Florida, United States, 33756
        • Athersys Investigational Site 129
      • Miami, Florida, United States, 33136
        • Athersys Investigational Site 108
    • Georgia
      • Augusta, Georgia, United States, 30912
        • Athersys Investigational Site 103
    • Illinois
      • Chicago, Illinois, United States, 60201
        • Athersys Investigational Site 121
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • Athersys Investigational Site 119
      • Wichita, Kansas, United States, 67214
        • Athersys Investigational Site 124
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Athersys Investigational Site 113
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • Athersys Investigational Site 125
    • Mississippi
      • Jackson, Mississippi, United States, 39216
        • Athersys Investigational Site 111
    • Ohio
      • Akron, Ohio, United States, 44304
        • Athersys Investigational Site 109
      • Cleveland, Ohio, United States, 44195
        • Athersys Investigational Site 104
      • Toledo, Ohio, United States, 43606
        • Athersys Investigational Site 130
    • Oregon
      • Portland, Oregon, United States, 97239
        • Athersys Investigational Site 102
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Athersys Investigational Site 107
      • Pittsburgh, Pennsylvania, United States, 15213
        • Athersys Investigational Site 106
    • South Carolina
      • Columbia, South Carolina, United States, 29203
        • Athersys Investigational Site 118
    • Tennessee
      • Chattanooga, Tennessee, United States, 37403
        • Athersys Investigational Site 115
    • Texas
      • Houston, Texas, United States, 77030
        • Athersys Investigational Site 101
      • Houston, Texas, United States, 77030
        • Athersys Investigational Site 105
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Athersys Investigational Site 110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Primary Inclusion Criteria:

  • Male or female subjects ≥18 years of age
  • Clinical diagnosis of ischemic stroke involving cerebral cortex
  • Occurrence of a moderate to moderately severe stroke with a persistent neurologic deficit documented by a NIHSS score of 8 to 20 (inclusive) that does not change by ≥4 points during the initial screening period
  • A mRS score of 0 or 1 prior to the onset of symptoms of the current stroke

Primary Exclusion Criteria:

  • Presence of a lacunar or a brainstem infarct
  • Comatose state
  • Brain hemorrhage
  • Major neurological event such as stroke or clinically significant head trauma within 6 months of enrollment into the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
single intravenous infusion 18-36 hours after stroke
Experimental: MultiStem
1.2 billion cells
single intravenous infusion 18-36 hours after stroke

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
assessment of disability by examining the distribution of modified Rankin Scale (mRS) scores [scale range = 0 to 6] evaluated by shift analysis
Time Frame: 90 days
90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
proportion of subjects achieving an excellent functional outcome defined by all of the following criteria:
Time Frame: 365 days
mRS score = 0 to 1 [scale range 0 to 6]; and NIHSS score = 0 to 1 [scale range 0 to 42]; and Barthel Index score = greater than or equal to 95 [scale range 0 to 100]
365 days
proportion of subjects achieving an excellent functional outcome defined by all of the following criteria:
Time Frame: 90 days
mRS score = 0 to 1 [scale range 0 to 6]; and NIHSS score = 0 to 1 [scale range 0 to 42]; and Barthel Index score = greater than or equal to 95 [scale range 0 to 100]
90 days
proportion of subjects with a mRS score of less than or equal to 2 [scale range 0 to 6] demonstrating the ability to function independently
Time Frame: 90 days
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Robert W Mays, PhD, Healios K.K.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 28, 2018

Primary Completion (Actual)

October 1, 2024

Study Completion (Actual)

October 1, 2024

Study Registration Dates

First Submitted

May 23, 2018

First Submitted That Met QC Criteria

May 23, 2018

First Posted (Actual)

June 4, 2018

Study Record Updates

Last Update Posted (Actual)

August 11, 2026

Last Update Submitted That Met QC Criteria

August 9, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe